Minority Predoctoral Fellowship Program
少数族裔博士前奖学金计划
基本信息
- 批准号:7618860
- 负责人:
- 金额:$ 2.63万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-03-01 至 2011-02-28
- 项目状态:已结题
- 来源:
- 关键词:Androgen ReceptorAndrogensAnti-Inflammatory AgentsAnti-inflammatoryBreast Cancer CellCell CommunicationCell LineCell SurvivalCell physiologyCellsChronicComplexCountryDefense MechanismsDiseaseDry Eye SyndromesEpithelialEpithelial CellsEstrogen Receptor alphaEstrogen ReceptorsEtiologyExcessive tearingEye diseasesFellowship ProgramFemaleFigs - dietaryFilmGenderGenetic TranscriptionGoalsGrowthHomeostasisHumanInflammationKeratoconjunctivitis SiccaLaboratoriesLacrimal gland structureMCF7 cellMaintenanceMediatingMinorityMolecularMucin-1 Staining MethodMucinsPathogenesisPersonsPlayPopulationPostmenopauseProductionPropertyProteinsRNA SplicingRoleSignal TransductionStressSystemTestingThinkingTissuesVariantWomanaqueousbiological adaptation to stressevaporationeye drynesshormone regulationnovelocular surfacepre-doctoralprotective effect
项目摘要
DESCRIPTION (provided by applicant): Dry eye disease is due to tear deficiency or excessive tear evaporation and results in inflammation and damage to the ocular surface. Mucins are highly O-glycosylated proteins that lubricate and protect the ocular surface. Recent findings indicate that the mucin MUC1 has anti-inflammatory properties and also can interact with estrogen receptor-alpha thereby modulating gene transcription. Androgens are key to maintaining homeostasis of the ocular surface. A potential interaction between MUC1 and androgen receptor (AR) could confer additional protection: My long term goal is to elucidate the molecular mechanisms involved in the pathogenesis of dry eye. My hypothesis is that MUC1 and androgen receptor (AR) are key factors that can act together to protect the ocular surface. The hypothesis will be tested by three specific aims: Aim 1- Determine the interaction between MUC1 and AR in human ocular surface epithelial cell lines; Aim 2- Elucidate the anti-inflammatory role of MUC1 and AR in those cells; and Aim 3- We have found that persons expressing the MUC1/A splice variant rather than MUC1/B are less susceptible to dry eye. We will determine if MUC1/A and MUC1/B splice variants differ in their signal transduction capabilities.
描述(由申请人提供):干眼症是由于撕裂缺乏或泪水蒸发过多,导致炎症和对眼表面的损害。粘蛋白是高度O-糖基化的蛋白,可润滑并保护眼表面。最近的发现表明,粘蛋白MUC1具有抗炎特性,也可以与雌激素受体-Alpha相互作用,从而调节基因转录。雄激素是维持眼表面体内平衡的关键。 MUC1与雄激素受体(AR)之间的潜在相互作用可以提供额外的保护:我的长期目标是阐明干眼症发病机理所涉及的分子机制。我的假设是MUC1和雄激素受体(AR)是可以共同作用以保护眼表面的关键因素。该假设将通过三个特定目的来检验:目标1-确定人眼表面上皮细胞系中MUC1和AR之间的相互作用;瞄准2-阐明MUC1和AR在这些细胞中的抗炎作用; AIM 3-我们发现表达MUC1/A剪接变体而不是MUC1/B的人不太容易受到干眼的影响。我们将确定MUC1/A和MUC1/B剪接变体的信号转导功能是否有所不同。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
YOANNIS IMBERT-FERNANDEZ其他文献
YOANNIS IMBERT-FERNANDEZ的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('YOANNIS IMBERT-FERNANDEZ', 18)}}的其他基金
Targeting 6-Phosphofructo-2-Kinase to increase efficacy of CDK4/6 Inhibitors
靶向 6-Phosphofructo-2-Kinase 以提高 CDK4/6 抑制剂的功效
- 批准号:
10650304 - 财政年份:2020
- 资助金额:
$ 2.63万 - 项目类别:
Targeting 6-Phosphofructo-2-Kinase to increase efficacy of CDK4/6 Inhibitors
靶向 6-Phosphofructo-2-Kinase 以提高 CDK4/6 抑制剂的功效
- 批准号:
10052862 - 财政年份:2020
- 资助金额:
$ 2.63万 - 项目类别:
Targeting 6-Phosphofructo-2-Kinase to increase efficacy of CDK4/6 Inhibitors
靶向 6-Phosphofructo-2-Kinase 以提高 CDK4/6 抑制剂的功效
- 批准号:
10430005 - 财政年份:2020
- 资助金额:
$ 2.63万 - 项目类别:
Targeting 6-Phosphofructo-2-Kinase to increase efficacy of CDK4/6 Inhibitors
靶向 6-Phosphofructo-2-Kinase 以提高 CDK4/6 抑制剂的功效
- 批准号:
10213670 - 财政年份:2020
- 资助金额:
$ 2.63万 - 项目类别:
相似国自然基金
甘氨脱氧胆酸通过FXR-FABP6促进雄激素转化代谢而改善PCOS的分子机制研究
- 批准号:82371643
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
当归多糖微针介导毛囊靶向递送巨噬细胞仿胞外囊泡治疗雄激素性脱发研究
- 批准号:82304732
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
雄激素通过免疫因子调控鹿茸再生的研究
- 批准号:32370899
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
黄芩苷抑制AR核转位在抗雄激素源性脱发中的作用及机制研究
- 批准号:82304649
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
DPP4通过GPx4和15-LOX双信号途径诱导毛乳头细胞铁死亡在雄激素性秃发毛囊微型化中的作用及机制
- 批准号:82304058
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Therapy-induced cognitive impairment in a rat model of prostate cancer
前列腺癌大鼠模型中治疗引起的认知障碍
- 批准号:
10766874 - 财政年份:2023
- 资助金额:
$ 2.63万 - 项目类别:
Leveraging PMN immune response to overcome ADT resistance in bone metastatic prostate cancer
利用 PMN 免疫反应克服骨转移性前列腺癌的 ADT 耐药性
- 批准号:
10684116 - 财政年份:2022
- 资助金额:
$ 2.63万 - 项目类别:
Leveraging PMN immune response to overcome ADT resistance in bone metastatic prostate cancer
利用 PMN 免疫反应克服骨转移性前列腺癌的 ADT 耐药性
- 批准号:
10522915 - 财政年份:2022
- 资助金额:
$ 2.63万 - 项目类别:
Role of Testosterone in Modulating Tau Pathogenesis in Females
睾酮在调节女性 Tau 发病机制中的作用
- 批准号:
10685501 - 财政年份:2022
- 资助金额:
$ 2.63万 - 项目类别:
Promoting DEIA in Lung Disease Research Through a Mentored Training Experience at IUB-SPH
通过 IUB-SPH 的指导培训经验促进 DEIA 在肺部疾病研究中的应用
- 批准号:
10792180 - 财政年份:2021
- 资助金额:
$ 2.63万 - 项目类别: